WO 2005/093423 PCT/EP2005/002588

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with Peroxisome Proliferative Activated Receptor alpha (PPARA) <130> BHC 04 01 091 <160> 5 <170> PatentIn version 3.2 <210> 1 <211> 1850 <212> DNA <213> Homo sapiens <400> 1 ggcccaggct gaagctcagg gccctgtctg ctctgtggac tcaacagttt gtggcaagac 60 120 aagctcagaa ctgagaagct gtcaccacag ttctggaggc tgggaagttc aagatcaaag tgccagcaga ttcagtgtca tgtgaggacg tgcttcctgc ttcatagata agagcttgga 180 gcteggegea caaccageac catetggteg cgatggtgga caeggaaage ccaetetgee 240 ccctctcccc actcgaggcc ggcgatctag agagcccgtt atctgaagag ttcctgcaag 300 aaatgggaaa catccaagag atttcgcaat ccatcggcga ggatagttct ggaagctttg 360 420 gctttacgga ataccagtat ttaggaagct gtcctggctc agatggctcg gtcatcacgg 480 acacgettte accagetteg ageceeteet eggtgactta teetgtggte eeeggeageg 540 tggacgagtc tcccagtgga gcattgaaca tcgaatgtag aatctgcggg gacaaggcct 600 caggetatea ttacggagte cacgegtgtg aaggetgeaa gggettettt eggegaacga ttcgactcaa gctggtgtat gacaagtgcg accgcagctg caagatccag aaaaagaaca 660 720 gaaacaaatg ccagtattgt cgatttcaca agtgcctttc tgtcgggatg tcacacaacg cgattcgttt tggacgaatg ccaagatctg agaaagcaaa actgaaagca gaaattctta 780 840 cctgtgaaca tgacatagaa gattctgaaa ctgcagatct caaatctctg gccaagagaa 900 tctacgaggc ctacttgaag aacttcaaca tgaacaaggt caaagcccgg gtcatcctct caggaaaggc cagtaacaat ccaccttttg tcatacatga tatggagaca ctgtgtatgg 960 1020 ctgagaagac gctggtggcc aagctggtgg ccaatggcat ccagaacaag gaggcggagg tecgeatett teaetgetge eagtgeaegt eagtggagae egteaeggag eteaeggaat 1080 tcgccaaggc catcccaggc ttcgcaaact tggacctgaa cgatcaagtg acattgctaa 1140 aatacggagt ttatgaggcc atattcgcca tgctgtcttc tgtgatgaac aaagacggga 1200 1260 tgctggtagc gtatggaaat gggtttataa ctcgtgaatt cctaaaaagc ctaaggaaac cgttctgtga tatcatggaa cccaagtttg attttgccat gaagttcaat gcactggaac 1320 tggatgacag tgatatctcc ctttttgtgg ctgctatcat ttgctgtgga gatcgtcctg 1380 gccttctaaa cgtaggacac attgaaaaaa tgcaggaggg tattgtacat gtgctcagac 1440 tocacotgoa gagoaaccao coggacgata totttotott cocaaaactt ottoaaaaaa 1500 1560 tggcagacct ccggcagctg gtgacggagc atgcgcagct ggtgcagatc atcaagaaga 1620 cggagtcgga tgctgcgctg cacccgctac tgcaggagat ctacagggac atgtactgag ttccttcaga tcagccacac cttttccagg agttctgaag ctgacagcac tacaaaggag 1680 1740 acgggggagc agcacgattt tgcacaaata tccaccactt taaccttaga gcttggacag

tetgagetgt aggtaacegg catattatte catatetttg ttttaaceag taettetaag

agcatagaac tcaaatgctg ggggaggtgg ctaatctcag gactgggaag

1800 1850

<21	0>	2													
<211>		468													
<212>		PRT													
<213> Hor		Homo	sap:	iens											
<40	0 >	2													
Met	Val	Asp	Thr	Glu	Ser	Pro	Leu	Cys	Pro	Leu	Ser	Pro	Leu	Glu	Ala
1		,		5			•	*	10		•			15	,
Gly	Asp	Leu	Glu	Ser	Pro	Leu	Ser	Glu	Glu	Phe	Leu	Gln	Glu	Met	Gly
			20					25			-		30		
Asn	Ile	Gln	Glu	Ile	Ser	Gln	Ser	Ile	Gly	Glu	Asp	Ser	Ser	Gly	Ser
		35	*				40	•				45			
Phe	Gly	Phe	Thr	Glu	Tyr	Gln	Tyr	Leu	Gly	Ser	Cys	Pro	Gly	Ser	Asp
	50				•	55	,				60				
Gly	Ser	Val	Ile	Thr	Asp	Thr	Leu	Ser	Pro	Ala	Ser	Ser	Pro	Ser	Ser
65					70					75		•			80
Val	Thr	Tyr	Pro	Val	Val	Pro	Gly	Ser	Va:1	Asp	Glu	Ser	Pro	Ser	Gly
				85					90					95	
Ala	Leu	Asn		Glu	Cys	Arg	Ile	-	Gly	Asp	Lys	Ala		Gly	Tyr
			100	,				105					110		
His	Tyr	Gly	Val	His	Ala	Cys		Gly	Суз	Lys	Gly			Arg	Arg
		115	_	. ,	_	·	120			_		125		_	
		Arg	Leu	Lys	Leu		Tyr	Asp	Lys	Cys	_	Arg	Ser	Cys	Lys
~ ~	130	T	T	<b>3</b>	7	135	T	G	G7	·	140	3	m1	T73 _	<b>T -</b>
145	GTII	Lys	цуs	ASII	150	ASII	туз	Cys	GIII	155	_	Arg	Pue	HIS	160
	T.011	Ser	ר בעד	G] vr		Sor	ui e	λαπ	7.7 -			Dho	<i>α</i> 1	7 ~~~	
Cys	neu	per	VAL	165	Mec	Ser	nrs	ASII	170	TTE		FIIE	GLY.	175	Met
Pro	Ara	Ser	GT 11		- АЛа	Tays	T.e.i	Lvs		Glu	Tle	T.e.11	Thr		GI 11
	3		180	-1-		-1-		185					190	0,7 2	
His	Asp	Ile		Asp	Ser	Glu	Thr		Asp	Leu	Lys	Ser		Ala	Lvs
	_	195		_			200		-		-	205			-
Arg	Ile	Tyr.	Glu	Ala	Tyr	Leu	Lys	Asn	Phe	Asn	Met	Asn	Lys	Val	Lys
	210				-	215					220				
Ala	Arg	Val	Ile	Leu	Ser	Gly	Lys	Ala	Ser	Asn	Asn	Pro	Pro	Phe	Val
225					230				•	235					240
Ile	His	Asp	Met	Glu	Thr	Leu	Cys	Met	Ala	Glu	Lys	Thr	Leu	Val	Ala
				245					250			•		255	
Lys	Leu	Val	Ala	Asn	Gly	Ile	Gln	Asn	Lys	Glu	Ala	Glu	Val	Arg	Ile
			260					265					270		
Phe	His	Cys	Cys	Gln	Cys	Thr	Ser	Val	Glu	Thr	Val	Thr	Glu	Leu	Thr
		275					280					285			
Glu	Phe	Ala	Lys	Ala	Ile	Pro	Gly	Phe	Ala	Asn	Leu	Asp	Leu	Asn	Asp
	290					295					300				
Gln	Val	Thr	Leu	Leu	Lys	Tyr	Gly	۷al	Tyr	Glu	Ala	Ile	Phe	Ala	Met
305					310					315					320

Leu Ser Ser Val Met Asn Lys Asp Gly Met Leu Val Ala Tyr Gly Asn 325 330 Gly Phe Ile Thr Arg Glu Phe Leu Lys Ser Leu Arg Lys Pro Phe Cys 345 Asp Ile Met Glu Pro Lys Phe Asp Phe Ala Met Lys Phe Asn Ala Leu . 360 Glu Leu Asp Asp Ser Asp Ile Ser Leu Phe Val Ala Ala Ile Ile Cys 375 Cys Gly Asp Arg Pro Gly Leu Leu Asn Val Gly His Ile Glu Lys Met 390 395 Gln Glu Gly Ile Val His Val Leu Arg Leu His Leu Gln Ser Asn His 405 410 Pro Asp Asp Ile Phe Leu Phe Pro Lys Leu Leu Gln Lys Met Ala Asp 425 Leu Arg Gln Leu Val Thr Glu His Ala Gln Leu Val Gln Ile Ile Lys 440 Lys Thr Glu Ser Asp Ala Ala Leu His Pro Leu Leu Gln Glu Ile Tyr 455 460 Arg Asp Met Tyr 465 <210> 3 <211> 23 <212> DNA <213> artificial sequence <220> <223> forward primer <400> 3 ccaagtttga ttttgccatg aag 23 <210> 4 <211> 21 <212> DNA <213> artificial sequence <220> <223> reverse primer <400> 4 agcagccaca aaaagggaga t 21 <210> 5 <211> 28 <212> DNA <213> artificial sequence <220> <223> probe <400> 5 tcaatgcact ggaactggat gacagtga 28